Entity
Description
  • Value proposition

    Biomorphic Programmable Polymers

    TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function.

    Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas.

    Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices.

    We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.

    Medical Device, MedTech, Synthetic Polymers, Tissue Reconstruction, and Innovation

  • Original language

    Biomorphic Programmable Polymers

    TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function.

    Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas.

    Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices.

    We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.

  • Tissue Reconstruction Solutions | TISSIUM Biomorphic Programmable Polymers

    TISSIUM is creating the future of tissue reconstruction. Learn more about our novel solutions based on our proprietary platform of biomorphic programmable polymers.

  • https://tissium.com/
Corporate interactions BETA
Corporate TypeTweets Articles
ZEBOX
ZEBOX
Startup accelerator & VC, Venture Capital and Private Equity Principals
ZEBOX
Startup accelerator & VC, Venture Capital and Private Equity Principals
Other

8 May 2023


SUEZ
SUEZ
Environment, Environmental Services
SUEZ
Environment, Environmental Services
Other

22 Oct 2019


Sofinnova Partners
Sofinnova Partners
Financial Services
Sofinnova Partners
Financial Services
Capitalistic
Partnership
Not event

31 Aug 2021

25 May 2024



EU-Startups
EU-Startups
Media, Software Development
EU-Startups
Media, Software Development
Capitalistic
Not partnership
Not event

31 Aug 2021


Omnes
Omnes
Startup accelerator & VC, Financial Services
Omnes
Startup accelerator & VC, Financial Services
Other

20 Nov 2019


La French Tech
La French Tech
Media, Government Administration
La French Tech
Media, Government Administration
Not capitalistic
Partnership
Not event

9 Sep 2024


Le Figaro
Le Figaro
Media, Newspaper Publishing
Le Figaro
Media, Newspaper Publishing
Not capitalistic
Not partnership
Event

5 Dec 2021


Similar entities
Loading...
Loading...
Social network dynamics